Design Therapeutics, Inc.
For the period ended Sep 30, 2026. Filed Nov 4, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2026 · Filed Nov 4, 2026
DSGN$10.65-1.4%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Statements of Cash Flows
(in thousands)
| Nine Months Ended September 30, | ||
|---|---|---|
| 2026 | 2025 | |
| Cash flows from operating activities | ||
| Net loss | $(58,089) | $(53,795) |
| Reconciliation of net loss to net cash used in operating activities: | ||
| Depreciation | 444 | 466 |
| Stock-based compensation | 11,842 | 11,114 |
| Amortization of premiums on investment securities, net | (144) | (2,741) |
| Non-cash lease expense | 145 | (13) |
| Deferred financing costs | — | 427 |
| Change in operating assets and liabilities: | ||
| Prepaid expense and other assets | (1,416) | (496) |
| Accounts payable and other liabilities | (115) | 2,646 |
| Net cash used in operating activities | (47,333) | (42,392) |
| Cash flows from investing activities | ||
| Purchases of investment securities | (94,808) | (204,155) |
| Proceeds from maturities of investment securities | 102,500 | 238,810 |
| Purchases of property and equipment | (36) | (159) |
| Net cash provided by investing activities | 7,656 | 34,496 |
| Cash flows from financing activities | ||
| Proceeds from the issuance of common stock in at-the-market offering, net of issuance costs | 37,164 | — |
| Issuance of common stock through employee stock purchase plan | 464 | 361 |
| Proceeds from the exercise of stock options | 445 | 60 |
| Net cash provided by financing activities | 38,073 | 421 |
| Net decrease in cash and cash equivalents | (1,604) | (7,475) |
| Cash and cash equivalents at beginning of period | 16,856 | 22,563 |
| Cash and cash equivalents at end of period | $15,252 | $15,088 |
| Supplemental disclosures | ||
| Financing costs included in accrued liabilities | $48 | $— |
| Increase in right-of-use-asset and operating lease liability related to lease amendment | $1,295 | $— |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.